• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Stroke prevention in patients with atrial fibrillation (AF) is one pillar of the management of
this common arrhythmia. Substantial advances in the epidemiology and associated …

Exclusion of the left atrial appendage to reduce thromboembolic risk related to atrial
fibrillation was first performed surgically in 1949. Over the past 2 decades, the field of …

Background: No study has so far compared Amulet with the new Watchman FLX in terms of
residual left atrial appendage (LAA) patency or clinical outcomes in patients undergoing …

Background Pivotal trials of percutaneous left atrial appendage occlusion (LAAO) used
specific postprocedure treatment protocols. Objectives This study sought to evaluate …

Abstract Background In the US Food and Drug Administration (FDA) clinical trials of left atrial
appendage (LAA) closure, a postimplantation peridevice leak (PDL) of≤ 5 mm (PDL≤ 5) …

Background Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in
clinical practice. The aim of this review was to evaluate the progress made in the …

The field of left atrial appendage occlusion is rapidly evolving. However, several issues
remain including the limited randomized efficacy data, peri-device leak, device-related …

Objectives The aim of this study was to report 1-year clinical outcomes following commercial
transcatheter left atrial appendage occlusion (LAAO) in the United States. Background The …

Background Procedural complications limit the clinical benefit of transcatheter left atrial
appendage occlusion (LAAO). Next-generation devices incorporate design modifications …